The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study

Authors :: Traverse-Glehen, Alexandra
Damotte, Diane
Dartigues, Peggy
Martin, Laurent
Parrens, Marie
Guesquieres, Hervé
Sarkozy, Clementine
Deau, Bénédicte
Bouabdallah, Reda
Garciaz, Sylvain
Meignan, Michel
Edeline, Véronique
Kanoun, Salim
Berriolo-Riedinger, Alina
Brice, Pauline
Rossi, Cedric
Stamatoullas, Aspasia
Veillard, Anne Sophie
Andre, Marc
Casasnovas, Olivier
Source :: Blood; December 2016, Vol. 128 Issue: 22 p1825-1825, 1p
Publication Year :: 2016
Abstract: Brice: Takeda Pharmaceuticals International Co.: Honoraria, Research Funding; Bristol Myers-Squibb: Honoraria; Seattle Genetics: Research Funding; Gilead: Honoraria; Roche: Honoraria. Casasnovas:BMS: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Research Funding; ROCHE: Consultancy, Honoraria, Research Funding.

Full Text Access

Tools